Surgery versus radiation therapy for stage IB2 cervical carcinoma

A population-based analysis

Bunja Jane Rungruang, Madeleine Courtney-Brooks, Sushil Beriwal, Kristin K. Zorn, Scott D. Richard, Alexander B. Olawaiye, Thomas C. Krivak, Paniti Sukumvanich

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Objective: The objective of the study was to examine outcomes in stage IB2 cervical cancer patients undergoing primary surgery versus radiation. Methods: Stage IB2 cervical cancer patients were identified from the Surveillance, Epidemiology and End Results Public-Use Database from 2000 to 2006. Patients were divided into those receiving radiation (radiation first) or surgery (surgery first) as initial treatment. Overall survival was calculated by Kaplan-Meier method and compared using log-rank test. Results: In total, 770 patients were identified with stage IB2 cervical cancer; 369 received radiation, and 401 received surgery initially. The radiation-first group had larger mean tumor size than the surgery-first group (6.0 vs 5.5 cm, respectively; P < 0.0001). The overall survival was longer in the surgery-first group compared with the radiation-first group (72.0 vs 61.4 months, respectively; P < 0.0001). Conclusions: Patients undergoing surgery as initial treatment for stage IB2 cervical cancer appear to have improved outcomes in the current era of chemoradiation; however, given the lack of chemotherapy information, a randomized trial will be necessary to see if these results remain valid.

Original languageEnglish (US)
Pages (from-to)484-489
Number of pages6
JournalInternational Journal of Gynecological Cancer
Volume22
Issue number3
DOIs
StatePublished - Mar 1 2012
Externally publishedYes

Fingerprint

Radiotherapy
Carcinoma
Radiation
Uterine Cervical Neoplasms
Population
Survival
Epidemiology
Databases
Drug Therapy
Therapeutics
Neoplasms

Keywords

  • Cervical cancer
  • Chemoradiation
  • Radiation
  • Radical hysterectomy

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynecology

Cite this

Surgery versus radiation therapy for stage IB2 cervical carcinoma : A population-based analysis. / Rungruang, Bunja Jane; Courtney-Brooks, Madeleine; Beriwal, Sushil; Zorn, Kristin K.; Richard, Scott D.; Olawaiye, Alexander B.; Krivak, Thomas C.; Sukumvanich, Paniti.

In: International Journal of Gynecological Cancer, Vol. 22, No. 3, 01.03.2012, p. 484-489.

Research output: Contribution to journalArticle

Rungruang, BJ, Courtney-Brooks, M, Beriwal, S, Zorn, KK, Richard, SD, Olawaiye, AB, Krivak, TC & Sukumvanich, P 2012, 'Surgery versus radiation therapy for stage IB2 cervical carcinoma: A population-based analysis', International Journal of Gynecological Cancer, vol. 22, no. 3, pp. 484-489. https://doi.org/10.1097/IGC.0b013e31823f890f
Rungruang, Bunja Jane ; Courtney-Brooks, Madeleine ; Beriwal, Sushil ; Zorn, Kristin K. ; Richard, Scott D. ; Olawaiye, Alexander B. ; Krivak, Thomas C. ; Sukumvanich, Paniti. / Surgery versus radiation therapy for stage IB2 cervical carcinoma : A population-based analysis. In: International Journal of Gynecological Cancer. 2012 ; Vol. 22, No. 3. pp. 484-489.
@article{3d0ed48ddab74be194f3153f68e4d18e,
title = "Surgery versus radiation therapy for stage IB2 cervical carcinoma: A population-based analysis",
abstract = "Objective: The objective of the study was to examine outcomes in stage IB2 cervical cancer patients undergoing primary surgery versus radiation. Methods: Stage IB2 cervical cancer patients were identified from the Surveillance, Epidemiology and End Results Public-Use Database from 2000 to 2006. Patients were divided into those receiving radiation (radiation first) or surgery (surgery first) as initial treatment. Overall survival was calculated by Kaplan-Meier method and compared using log-rank test. Results: In total, 770 patients were identified with stage IB2 cervical cancer; 369 received radiation, and 401 received surgery initially. The radiation-first group had larger mean tumor size than the surgery-first group (6.0 vs 5.5 cm, respectively; P < 0.0001). The overall survival was longer in the surgery-first group compared with the radiation-first group (72.0 vs 61.4 months, respectively; P < 0.0001). Conclusions: Patients undergoing surgery as initial treatment for stage IB2 cervical cancer appear to have improved outcomes in the current era of chemoradiation; however, given the lack of chemotherapy information, a randomized trial will be necessary to see if these results remain valid.",
keywords = "Cervical cancer, Chemoradiation, Radiation, Radical hysterectomy",
author = "Rungruang, {Bunja Jane} and Madeleine Courtney-Brooks and Sushil Beriwal and Zorn, {Kristin K.} and Richard, {Scott D.} and Olawaiye, {Alexander B.} and Krivak, {Thomas C.} and Paniti Sukumvanich",
year = "2012",
month = "3",
day = "1",
doi = "10.1097/IGC.0b013e31823f890f",
language = "English (US)",
volume = "22",
pages = "484--489",
journal = "International Journal of Gynecological Cancer",
issn = "1048-891X",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Surgery versus radiation therapy for stage IB2 cervical carcinoma

T2 - A population-based analysis

AU - Rungruang, Bunja Jane

AU - Courtney-Brooks, Madeleine

AU - Beriwal, Sushil

AU - Zorn, Kristin K.

AU - Richard, Scott D.

AU - Olawaiye, Alexander B.

AU - Krivak, Thomas C.

AU - Sukumvanich, Paniti

PY - 2012/3/1

Y1 - 2012/3/1

N2 - Objective: The objective of the study was to examine outcomes in stage IB2 cervical cancer patients undergoing primary surgery versus radiation. Methods: Stage IB2 cervical cancer patients were identified from the Surveillance, Epidemiology and End Results Public-Use Database from 2000 to 2006. Patients were divided into those receiving radiation (radiation first) or surgery (surgery first) as initial treatment. Overall survival was calculated by Kaplan-Meier method and compared using log-rank test. Results: In total, 770 patients were identified with stage IB2 cervical cancer; 369 received radiation, and 401 received surgery initially. The radiation-first group had larger mean tumor size than the surgery-first group (6.0 vs 5.5 cm, respectively; P < 0.0001). The overall survival was longer in the surgery-first group compared with the radiation-first group (72.0 vs 61.4 months, respectively; P < 0.0001). Conclusions: Patients undergoing surgery as initial treatment for stage IB2 cervical cancer appear to have improved outcomes in the current era of chemoradiation; however, given the lack of chemotherapy information, a randomized trial will be necessary to see if these results remain valid.

AB - Objective: The objective of the study was to examine outcomes in stage IB2 cervical cancer patients undergoing primary surgery versus radiation. Methods: Stage IB2 cervical cancer patients were identified from the Surveillance, Epidemiology and End Results Public-Use Database from 2000 to 2006. Patients were divided into those receiving radiation (radiation first) or surgery (surgery first) as initial treatment. Overall survival was calculated by Kaplan-Meier method and compared using log-rank test. Results: In total, 770 patients were identified with stage IB2 cervical cancer; 369 received radiation, and 401 received surgery initially. The radiation-first group had larger mean tumor size than the surgery-first group (6.0 vs 5.5 cm, respectively; P < 0.0001). The overall survival was longer in the surgery-first group compared with the radiation-first group (72.0 vs 61.4 months, respectively; P < 0.0001). Conclusions: Patients undergoing surgery as initial treatment for stage IB2 cervical cancer appear to have improved outcomes in the current era of chemoradiation; however, given the lack of chemotherapy information, a randomized trial will be necessary to see if these results remain valid.

KW - Cervical cancer

KW - Chemoradiation

KW - Radiation

KW - Radical hysterectomy

UR - http://www.scopus.com/inward/record.url?scp=84858204140&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84858204140&partnerID=8YFLogxK

U2 - 10.1097/IGC.0b013e31823f890f

DO - 10.1097/IGC.0b013e31823f890f

M3 - Article

VL - 22

SP - 484

EP - 489

JO - International Journal of Gynecological Cancer

JF - International Journal of Gynecological Cancer

SN - 1048-891X

IS - 3

ER -